ClinicalTrials.gg
CompletedNCT02336815STORMUpdated Jan 26, 2023Results posted

Selinexor Treatment of Refractory Myeloma

A Phase 2 interventional study of Selinexor and Dexamethasone in Multiple Myeloma, sponsored by Karyopharm Therapeutics Inc. Completed at 61 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
202
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing selinexor in Multiple Myeloma — 12 open to participants now, 21 under way, 3 of them phase 3. selinexor · Multiple Myeloma.

Enrollment
5th of 38
202 · median 45
Started
2015
with 2 others
Phase 2
19 of 38
6 open now
Registered
4th of 38
by date
Lead sponsor
6 of 38
Karyopharm Therapeutics Inc

Among the 38 studies testing selinexor in Multiple Myeloma, this one is the 5th largest by enrollment, is one of 3 that started in 2015, is one of 19 in phase 2, and was the 4th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 38 studies testing selinexor in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About selinexor

selinexor: first FDA approval 2019 (XPOVIO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing selinexor in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).

Read the detailed description

This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd), both dosed twice weekly in each four-week cycle, in patients with MM previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and daratumumab.

This study consists of two parts:

  • Part 1 enrolled patients with both quad-refractory MM and penta-refractory MM.
  • Part 2 will enroll patients with penta-refractory MM only.
03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple myeloma
  • Karyopharm
  • KPT-330
  • Selinexor
  • Refractory
  • Bortezomib
  • Carfilzomib
  • Lenalidomide
  • Pomalidomide
  • Dexamethasone
  • STORM
  • Daratumumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Measurable MM based on modified IMWG guidelines. Defined by at least one of the following:

  1. Serum M-protein ≥ 0.5 g/dL by serum electrophoresis (SPEP) or for IgA myeloma, by quantitative IgA
  2. Urinary M-protein excretion ≥ 200 mg/24 hours
  3. Free Light Chain (FLC) ≥ 100 mg/L, provided that the FLC ratio is abnormal
  4. If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement, then quantitative Ig levels by nephelometry or turbidimetry are acceptable

    • Must have previously received ≥ 3 anti-MM regimens including: an alkylating agent, lenalidomide, pomalidomide, bortezomib, carfilzomib, daratumumab, and a . There is no upper limit on the number of prior therapies provided that all other inclusion/exclusion criteria are met.
    • MM to previous treatment with one or more glucocorticoids, parenteral PI (i.e., bortezomib and/or carfilzomib), IMiD (i.e., lenalidomide and/or pomalidomide), and the anti-CD38 mAb, daratumumab. Refractory is defined as ≤ 25% response to therapy, or progression during therapy or progression within 60 days after completion of therapy.

Exclusion criteria

Exclusion Criteria:

  • Active smoldering MM.
  • Active plasma cell leukemia.
  • Documented systemic amyloid light chain amyloidosis.
  • Active CNS MM.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Part 1

    Participants with quad-exposed, double-class-refractory (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, but not an anti-CD38 mab) and penta-exposed, triple-class-refractory multiple myeloma (MM) (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and the anti-CD38 mAb daratumumab) received, two dosing schedules (1) Selinexor 80 milligrams (mg) plus low-dose dexamethasone 20 mg (Sd) twice-weekly on Days 1 and 3 for 3 weeks of each 4-week cycle (2) Selinexor 80 mg plus low-dose dexamethasone 20 mg (Sd) twice-weekly continuously in 4-week cycles; until disease progression, death, or unacceptable toxicity (maximum duration of approximately 13 months).

    Drug: Selinexor · Drug: Dexamethasone

  • Experimental
    Part 2

    Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, Selinexor 80 mg post oral (PO) plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).

    Drug: Selinexor · Drug: Dexamethasone

Interventions

  • Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)

    Also known as: KPT-330

  • 20 mg was given with each dose of Selinexor.

06

What researchers measure

Primary outcomes

  1. Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC)

    IRC assessed ORR per 2016 IMWG criteria: Percentage of participants who experienced Partial response (PR): greater than or equal to (\>=) 50 percent (%) reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to lesser than (\<) 200 mg per 24 hours; Very good partial response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and lesser than or equal to (\<=) 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined+Normal free light chain (FLC) ratio+Absence of clonal cells in bone marrow biopsy by immunohistochemistry).

    Time frame: Baseline until disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 17 months)

Secondary outcomes

  1. Part 1: Duration of Response (DoR) Per IMWG as Assessed by IRC

    IRC assessed DoR per 2016 IMWG criteria: time (in months) from the first documentation of objective response (confirmed CR or PR) to the date of first documentation of progressive disease (PD) or death due to any cause. Partial response (PR): \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 gram per deciliter (g/dL); Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urine M-protein (absolute increase must be \>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.

    Time frame: First response subsequently confirmed to disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 13 months)

  2. Part 2: Duration of Response (DoR) Per IMWG as Assessed by an IRC

    IRC assessed DoR per 2016 IMWG criteria: time (in months) from the first documentation of objective response (confirmed CR or PR) to the date of first documentation of progressive disease (PD) or death due to any cause. Partial response (PR): \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>= 5 g/dL; Urine M-protein (absolute increase must be \>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.

    Time frame: First response subsequently confirmed to disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 17 months)

  3. Part 1: Percentage of Participants With Clinical Benefit Rate (CBR) ) Per IMWG as Assessed by IRC

    IRC assessed CBR per 2016 IMWG criteria: Percentage of participants with a confirmed minimal response (MR) or better (PR, VGPR, CR or sCR) before confirmed disease progression or initiating new MM treatment. Minimal response (MR): \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Partial response (PR): \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; Very good partial response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined+Normal free light chain (FLC) ratio+Absence of clonal cells by immunohistochemistry).

    Time frame: Baseline up to a maximum of 13 months

  4. Part 2: Percentage of Participants With Clinical Benefit Rate (CBR) Per IMWG as Assessed by IRC

    IRC assessed CBR per 2016 IMWG criteria: Percentage of participants with a confirmed minimal response (MR) or better (PR, VGPR, CR or sCR) before confirmed disease progression or initiating new MM treatment. Minimal response (MR): \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Partial response (PR): \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; Very good partial response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined+Normal free light chain (FLC) ratio+Absence of clonal cells by immunohistochemistry).

    Time frame: Baseline up to a maximum of 17 months

  5. Part 1: Duration of Clinical Benefit Per IMWG as Assessed by IRC

    IRC assessed duration of clinical benefit per 2016 IMWG criteria: Duration from first response (at least MR) to time of IRC-determined PD or death due to disease progression, whichever occurs first. Minimal response (MR): \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.

    Time frame: First response subsequently confirmed to disease progression, or death, whichever occurred first (maximum duration of 13 months)

  6. Part 2: Duration of Clinical Benefit Per IMWG as Assessed by IRC

    IRC assessed duration of clinical benefit per 2016 IMWG criteria: Duration from first response (at least MR) to time of IRC-determined PD or death due to disease progression, whichever occurs first. Minimal response (MR): \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.

    Time frame: First response subsequently confirmed to disease progression, or death, whichever occurred first (maximum duration of 17 months)

  7. Part 2: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who achieved stable disease (SD) or better (MR, PR, VGPR, CR, sCR) for a minimum of 12 weeks. Stable disease (SD): Not recommended for use as an indicator of response; stability of disease was best described by providing the time to progression (TTP) estimates. MR: \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. PR: \>=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or sCR: CR as defined+Normal FLC ratio+Absence of clonal cells by immunohistochemistry).

    Time frame: Every 12 weeks until progressive disease or death due to any cause, up to 17 months

  8. Part 1: Progression Free Survival (PFS) Per IMWG as Assessed by IRC

    IRC assessed PFS per 2016 IMWG criteria: Duration from start of study treatment until IRC-determined progressive disease (PD) or death from any cause, whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>=1 g/dL if the lowest M-component was \>= 5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.

    Time frame: From start of study treatment to progression of disease or discontinuation from the study or death, whichever occurred first (maximum duration of 13 months)

  9. Part 2: Progression Free Survival (PFS) Per IMWG as Assessed by IRC

    IRC assessed PFS per 2016 IMWG criteria: Duration from start of study treatment until IRC-determined progressive disease (PD) or death from any cause, whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>=1 g/dL if the lowest M-component was \>= 5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.

    Time frame: From start of study treatment to progression of disease or discontinuation from the study or death, whichever occurred first (maximum duration of 17 months)

  10. Part 1: Time to Progression (TTP) Per IMWG as Assessed by IRC

    IRC assessed TTP per 2016 IMWG criteria: Duration from start of study treatment until PD or death due to PD (per IRC), whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>=1 g/dL if the lowest M-component was \>= 5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.

    Time frame: From start of study treatment to progression of disease or death, whichever occurred first (maximum duration of 13 months)

  11. Part 2: Time to Progression (TTP) Per IMWG as Assessed by IRC

    IRC assessed TTP per 2016 IMWG criteria: Duration from start of study treatment until PD or death due to PD (per IRC), whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>=1 g/dL if the lowest M-component was \>= 5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.

    Time frame: From start of study treatment to progression of disease or death, whichever occurred first (maximum duration of 17 months)

  12. Part 1: Time to Next Treatment (TTNT)

    TTNT was defined as the duration from start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurred first. Analysis was performed using Kaplan-Meier method.

    Time frame: From start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurs first (maximum duration of 13 months)

  13. Part 2: Time to Next Treatment (TTNT)

    TTNT was defined as the duration from start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurred first. Analysis was performed using Kaplan-Meier method.

    Time frame: From start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurs first (maximum duration of 17 months)

  14. Part 1: Overall Survival (OS)

    OS was defined as the duration (in months) from start of study treatment to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier. Analysis was performed using Kaplan-Meier method.

    Time frame: From start of study treatment to death (maximum duration of 13 months)

  15. Part 2: Overall Survival (OS)

    OS was defined as the duration (in months) from start of study treatment to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier. Analysis was performed using Kaplan-Meier method.

    Time frame: From start of study treatment to death (maximum duration of 17 months)

  16. Part 2: Change From Baseline in Health-related Quality of Life (HRQL) Score Based on Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT-MM) Questionnaire

    FACT-MM combines the general version of the FACT (FACT-G) with a MM-specific sub-scale (14 items). The sub-scales for the FACT-G are Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items), and Functional Well-Being (7 items). The trial outcomes index (TOI); total of 41 items) is the primary measurement of interest, comprised of the Physical and Functional sub-scales plus the MM-specific sub-scale. Each item is rated on a 5-point Likert scale, ranging from 0 ("Not at all") to 4 ("Very much"), therefore the TOI has a score ranging from 0 to 120. Higher scores indicated improvement in well being.

    Time frame: Baseline, Day 1 of Cycle 2 to Cycle 20 (up to a maximum of 17 months)

  17. Number of Participants With Treatment-Emergent Adverse Events (TEAE) of Grade 3/4, Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Treatment-emergent events are events between first dose of study drug and up to last dose of study treatment + 30 days (inclusive) that were absent before treatment or that worsened relative to pre-treatment state.

    Time frame: Baseline to 30 days after last dose of study treatment (maximum duration of 18 months)

  18. Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (TEAEs) of Grade 3/4, Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. A treatment related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage.

    Time frame: Baseline to 30 days after last dose of study treatment (maximum duration of 18 months)

  19. Apparent Clearance (CL/F) of Selinexor in Plasma

    CL/F of selinexor in plasma was reported.

    Time frame: Cycle 1: Day 1: Pre-dose, 1, 2 and 4 hours post-dose; Day 8 and 15: Pre-dose and 1 hour post-dose; Cycle 2: Day 1: Predose, 1, 2 and 4 hours post-dose

  20. Volume of Distribution (V/F) of Selinexor in Plasma

    Vz/F of selinexor in plasma was reported.

    Time frame: Cycle 1: Day 1: Pre-dose, 1, 2 and 4 hours post-dose; Day 8 and 15: Pre-dose and 1 hour post-dose; Cycle 2: Day 1: Predose, 1, 2 and 4 hours post-dose

07

Results

Posted Aug 13, 2020

Participant flow

Part 1 of the study was conducted at 32 sites in the United States and Part 2 of the study was conducted at 59 sites in France, Germany, Belgium, Greece, Austria and United States. Enrollment in both parts was between from 26 May 2015 (first participant first visit)) and 26 July 2019 (last participant last visit).

Participant flow — Overall Study
MilestonePart 1Part 2
Started79123
Completed00
Not completed79123
Withdrew: Disease progression4570
Withdrew: Adverse event1839
Withdrew: Physician decision114
Withdrew: Withdrawal by subject32
Withdrew: Lost to follow-up13
Withdrew: Other15

Outcome measures

PrimaryPart 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC)

IRC assessed ORR per 2016 IMWG criteria: Percentage of participants who experienced Partial response (PR): greater than or equal to (\>=) 50 percent (%) reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to lesser than (\<) 200 mg per 24 hours; Very good partial response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and lesser than or equal to (\<=) 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined+Normal free light chain (FLC) ratio+Absence of clonal cells in bone marrow biopsy by immunohistochemistry).

Time frame:
Baseline until disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 17 months)
Reported as:
Number · Percentage of Participants
Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC)
Percentage of ParticipantsPart 2
Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC)26.2 (18.7 to 35.0)
SecondaryPart 1: Duration of Response (DoR) Per IMWG as Assessed by IRC

IRC assessed DoR per 2016 IMWG criteria: time (in months) from the first documentation of objective response (confirmed CR or PR) to the date of first documentation of progressive disease (PD) or death due to any cause. Partial response (PR): \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 gram per deciliter (g/dL); Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urine M-protein (absolute increase must be \>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.

Time frame:
First response subsequently confirmed to disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 13 months)
Reported as:
Median · Months
Part 1: Duration of Response (DoR) Per IMWG as Assessed by IRC
MonthsPart 1
Part 1: Duration of Response (DoR) Per IMWG as Assessed by IRC6.2 (3.6 to 9.8)
SecondaryPart 2: Duration of Response (DoR) Per IMWG as Assessed by an IRC

IRC assessed DoR per 2016 IMWG criteria: time (in months) from the first documentation of objective response (confirmed CR or PR) to the date of first documentation of progressive disease (PD) or death due to any cause. Partial response (PR): \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>= 5 g/dL; Urine M-protein (absolute increase must be \>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.

Time frame:
First response subsequently confirmed to disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 17 months)
Reported as:
Median · Months
Part 2: Duration of Response (DoR) Per IMWG as Assessed by an IRC
MonthsPart 2
Part 2: Duration of Response (DoR) Per IMWG as Assessed by an IRC4.4 (3.7 to 10.8)
SecondaryPart 1: Percentage of Participants With Clinical Benefit Rate (CBR) ) Per IMWG as Assessed by IRC

IRC assessed CBR per 2016 IMWG criteria: Percentage of participants with a confirmed minimal response (MR) or better (PR, VGPR, CR or sCR) before confirmed disease progression or initiating new MM treatment. Minimal response (MR): \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Partial response (PR): \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; Very good partial response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined+Normal free light chain (FLC) ratio+Absence of clonal cells by immunohistochemistry).

Time frame:
Baseline up to a maximum of 13 months
Reported as:
Number · Percentage of Participants
Part 1: Percentage of Participants With Clinical Benefit Rate (CBR) ) Per IMWG as Assessed by IRC
Percentage of ParticipantsPart 1
Part 1: Percentage of Participants With Clinical Benefit Rate (CBR) ) Per IMWG as Assessed by IRC31.6 (21.6 to 43.1)
SecondaryPart 2: Percentage of Participants With Clinical Benefit Rate (CBR) Per IMWG as Assessed by IRC

IRC assessed CBR per 2016 IMWG criteria: Percentage of participants with a confirmed minimal response (MR) or better (PR, VGPR, CR or sCR) before confirmed disease progression or initiating new MM treatment. Minimal response (MR): \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Partial response (PR): \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; Very good partial response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined+Normal free light chain (FLC) ratio+Absence of clonal cells by immunohistochemistry).

Time frame:
Baseline up to a maximum of 17 months
Reported as:
Number · Percentage of Participants
Part 2: Percentage of Participants With Clinical Benefit Rate (CBR) Per IMWG as Assessed by IRC
Percentage of ParticipantsPart 2
Part 2: Percentage of Participants With Clinical Benefit Rate (CBR) Per IMWG as Assessed by IRC39.3 (30.6 to 48.6)
SecondaryPart 1: Duration of Clinical Benefit Per IMWG as Assessed by IRC

IRC assessed duration of clinical benefit per 2016 IMWG criteria: Duration from first response (at least MR) to time of IRC-determined PD or death due to disease progression, whichever occurs first. Minimal response (MR): \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.

Time frame:
First response subsequently confirmed to disease progression, or death, whichever occurred first (maximum duration of 13 months)
Reported as:
Median · Months
Part 1: Duration of Clinical Benefit Per IMWG as Assessed by IRC
MonthsPart 1
Part 1: Duration of Clinical Benefit Per IMWG as Assessed by IRC5.6 (4.4 to 10.3)
SecondaryPart 2: Duration of Clinical Benefit Per IMWG as Assessed by IRC

IRC assessed duration of clinical benefit per 2016 IMWG criteria: Duration from first response (at least MR) to time of IRC-determined PD or death due to disease progression, whichever occurs first. Minimal response (MR): \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.

Time frame:
First response subsequently confirmed to disease progression, or death, whichever occurred first (maximum duration of 17 months)
Reported as:
Median · Months
Part 2: Duration of Clinical Benefit Per IMWG as Assessed by IRC
MonthsPart 2
Part 2: Duration of Clinical Benefit Per IMWG as Assessed by IRC3.8 (3.2 to 10.9)
SecondaryPart 2: Disease Control Rate (DCR)

DCR was defined as the percentage of participants who achieved stable disease (SD) or better (MR, PR, VGPR, CR, sCR) for a minimum of 12 weeks. Stable disease (SD): Not recommended for use as an indicator of response; stability of disease was best described by providing the time to progression (TTP) estimates. MR: \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. PR: \>=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or sCR: CR as defined+Normal FLC ratio+Absence of clonal cells by immunohistochemistry).

Time frame:
Every 12 weeks until progressive disease or death due to any cause, up to 17 months
Reported as:
Number · Percentage of Participants
Part 2: Disease Control Rate (DCR)
Percentage of ParticipantsPart 2
Part 2: Disease Control Rate (DCR)44.3 (35.3 to 53.5)
SecondaryPart 1: Progression Free Survival (PFS) Per IMWG as Assessed by IRC

IRC assessed PFS per 2016 IMWG criteria: Duration from start of study treatment until IRC-determined progressive disease (PD) or death from any cause, whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>=1 g/dL if the lowest M-component was \>= 5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.

Time frame:
From start of study treatment to progression of disease or discontinuation from the study or death, whichever occurred first (maximum duration of 13 months)
Reported as:
Median · Months
Part 1: Progression Free Survival (PFS) Per IMWG as Assessed by IRC
MonthsPart 1
Part 1: Progression Free Survival (PFS) Per IMWG as Assessed by IRC4.7 (3.3 to 7.6)
SecondaryPart 2: Progression Free Survival (PFS) Per IMWG as Assessed by IRC

IRC assessed PFS per 2016 IMWG criteria: Duration from start of study treatment until IRC-determined progressive disease (PD) or death from any cause, whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>=1 g/dL if the lowest M-component was \>= 5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.

Time frame:
From start of study treatment to progression of disease or discontinuation from the study or death, whichever occurred first (maximum duration of 17 months)
Reported as:
Median · Months
Part 2: Progression Free Survival (PFS) Per IMWG as Assessed by IRC
MonthsPart 2
Part 2: Progression Free Survival (PFS) Per IMWG as Assessed by IRC3.7 (2.8 to 4.7)
SecondaryPart 1: Time to Progression (TTP) Per IMWG as Assessed by IRC

IRC assessed TTP per 2016 IMWG criteria: Duration from start of study treatment until PD or death due to PD (per IRC), whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>=1 g/dL if the lowest M-component was \>= 5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.

Time frame:
From start of study treatment to progression of disease or death, whichever occurred first (maximum duration of 13 months)
Reported as:
Median · Months
Part 1: Time to Progression (TTP) Per IMWG as Assessed by IRC
MonthsPart 1
Part 1: Time to Progression (TTP) Per IMWG as Assessed by IRC5.5 (3.3 to 10.7)
SecondaryPart 2: Time to Progression (TTP) Per IMWG as Assessed by IRC

IRC assessed TTP per 2016 IMWG criteria: Duration from start of study treatment until PD or death due to PD (per IRC), whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>=1 g/dL if the lowest M-component was \>= 5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.

Time frame:
From start of study treatment to progression of disease or death, whichever occurred first (maximum duration of 17 months)
Reported as:
Median · Months
Part 2: Time to Progression (TTP) Per IMWG as Assessed by IRC
MonthsPart 2
Part 2: Time to Progression (TTP) Per IMWG as Assessed by IRC4.1 (3.0 to 6.2)
SecondaryPart 1: Time to Next Treatment (TTNT)

TTNT was defined as the duration from start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurred first. Analysis was performed using Kaplan-Meier method.

Time frame:
From start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurs first (maximum duration of 13 months)
Reported as:
Median · Months
Part 1: Time to Next Treatment (TTNT)
MonthsPart 1
Part 1: Time to Next Treatment (TTNT)2.6 (1.8 to 4.2)
SecondaryPart 2: Time to Next Treatment (TTNT)

TTNT was defined as the duration from start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurred first. Analysis was performed using Kaplan-Meier method.

Time frame:
From start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurs first (maximum duration of 17 months)
Reported as:
Median · Months
Part 2: Time to Next Treatment (TTNT)
MonthsPart 2
Part 2: Time to Next Treatment (TTNT)3.2 (2.6 to 3.8)
SecondaryPart 1: Overall Survival (OS)

OS was defined as the duration (in months) from start of study treatment to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier. Analysis was performed using Kaplan-Meier method.

Time frame:
From start of study treatment to death (maximum duration of 13 months)
Reported as:
Median · Months
Part 1: Overall Survival (OS)
MonthsPart 1
Part 1: Overall Survival (OS)7.3 (5.8 to 10.9)
SecondaryPart 2: Overall Survival (OS)

OS was defined as the duration (in months) from start of study treatment to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier. Analysis was performed using Kaplan-Meier method.

Time frame:
From start of study treatment to death (maximum duration of 17 months)
Reported as:
Median · Months
Part 2: Overall Survival (OS)
MonthsPart 2
Part 2: Overall Survival (OS)8.4 (6.2 to 11.2)
SecondaryPart 2: Change From Baseline in Health-related Quality of Life (HRQL) Score Based on Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT-MM) Questionnaire

FACT-MM combines the general version of the FACT (FACT-G) with a MM-specific sub-scale (14 items). The sub-scales for the FACT-G are Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items), and Functional Well-Being (7 items). The trial outcomes index (TOI); total of 41 items) is the primary measurement of interest, comprised of the Physical and Functional sub-scales plus the MM-specific sub-scale. Each item is rated on a 5-point Likert scale, ranging from 0 ("Not at all") to 4 ("Very much"), therefore the TOI has a score ranging from 0 to 120. Higher scores indicated improvement in well being.

Time frame:
Baseline, Day 1 of Cycle 2 to Cycle 20 (up to a maximum of 17 months)
Reported as:
Mean · Score on a Scale
Part 2: Change From Baseline in Health-related Quality of Life (HRQL) Score Based on Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT-MM) Questionnaire
Score on a ScalePart 2
Trial Outcomes Index Score: Baseline67.5 ± 19.20
Trial Outcomes Index Score: Change at C2D1-6.1 ± 18.43
Trial Outcomes Index Score: Change at C3D1-8.5 ± 15.50
Trial Outcomes Index Score: Change at C4D1-9.1 ± 16.79
Trial Outcomes Index Score: Change at C5D1-6.9 ± 12.06
Trial Outcomes Index Score: Change at C6D1-8.3 ± 15.07
Trial Outcomes Index Score: Change at C7D1-7.5 ± 19.26
Trial Outcomes Index Score: Change at C8D1-15.4 ± 24.59
Trial Outcomes Index Score: Change at C9D1-4.7 ± 14.84
Trial Outcomes Index Score: Change at C10D1-4.0 ± 5.29
Trial Outcomes Index Score: Change at C11D13.0 ± NA
Trial Outcomes Index Score: Change at C12D13.0 ± NA
Trial Outcomes Index Score: Change at C13D1-23.0 ± NA
Trial Outcomes Index Score: Change at C14D114.0 ± NA
Trial Outcomes Index Score: Change at C15D11.0 ± NA
Trial Outcomes Index Score: Change at C16D14.0 ± NA
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAE) of Grade 3/4, Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Treatment-emergent events are events between first dose of study drug and up to last dose of study treatment + 30 days (inclusive) that were absent before treatment or that worsened relative to pre-treatment state.

Time frame:
Baseline to 30 days after last dose of study treatment (maximum duration of 18 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAE) of Grade 3/4, Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03
ParticipantsPart 1Part 2
Number of Participants With Treatment-Emergent Adverse Events (TEAE) of Grade 3/4, Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.0375115
SecondaryNumber of Participants With Treatment-Emergent Treatment-Related Adverse Events (TEAEs) of Grade 3/4, Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. A treatment related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage.

Time frame:
Baseline to 30 days after last dose of study treatment (maximum duration of 18 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (TEAEs) of Grade 3/4, Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03
ParticipantsPart 1Part 2
Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (TEAEs) of Grade 3/4, Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.0369110
SecondaryApparent Clearance (CL/F) of Selinexor in Plasma

CL/F of selinexor in plasma was reported.

Time frame:
Cycle 1: Day 1: Pre-dose, 1, 2 and 4 hours post-dose; Day 8 and 15: Pre-dose and 1 hour post-dose; Cycle 2: Day 1: Predose, 1, 2 and 4 hours post-dose
Reported as:
Mean · Liters/Hour
Apparent Clearance (CL/F) of Selinexor in Plasma
Liters/HourPart 1
Apparent Clearance (CL/F) of Selinexor in Plasma16.6 ± 2.8
SecondaryVolume of Distribution (V/F) of Selinexor in Plasma

Vz/F of selinexor in plasma was reported.

Time frame:
Cycle 1: Day 1: Pre-dose, 1, 2 and 4 hours post-dose; Day 8 and 15: Pre-dose and 1 hour post-dose; Cycle 2: Day 1: Predose, 1, 2 and 4 hours post-dose
Reported as:
Mean · Liter
Volume of Distribution (V/F) of Selinexor in Plasma
LiterPart 1
Volume of Distribution (V/F) of Selinexor in Plasma145.6 ± 28.2

Adverse events

Collected over Baseline to 30 days after last dose of study treatment (maximum duration of 18 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 120/79 (25.3%)45/79 (57%)79/79 (100%)
Part 228/123 (22.8%)78/123 (63.4%)123/123 (100%)
Most frequent serious events
Showing 10 of 126
Most frequent serious events
EventPart 1Part 2
PneumoniaInfections and infestations2/7914/123
SepsisInfections and infestations1/7912/123
ThrombocytopeniaBlood and lymphatic system disorders5/793/123
InfluenzaInfections and infestations4/791/123
HypercalcaemiaMetabolism and nutrition disorders4/790/123
Confusional statePsychiatric disorders4/794/123
Acute kidney injuryRenal and urinary disorders4/793/123
Febrile neutropeniaBlood and lymphatic system disorders3/790/123
NauseaGastrointestinal disorders3/792/123
PyrexiaGeneral disorders3/793/123
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPart 1Part 2
NauseaGastrointestinal disorders60/7988/123
ThrombocytopeniaBlood and lymphatic system disorders58/7991/123
FatigueGeneral disorders55/7977/123
AnaemiaBlood and lymphatic system disorders37/7980/123
Decreased appetiteMetabolism and nutrition disorders43/7968/123
Weight decreasedInvestigations39/7961/123
VomitingGastrointestinal disorders37/7947/123
DiarrhoeaGastrointestinal disorders35/7957/123
HyponatraemiaMetabolism and nutrition disorders34/7945/123
NeutropeniaBlood and lymphatic system disorders23/7949/123

Baseline characteristics

Safety population consisted of all participants, who had received at least 1 dose of study treatment (partial or complete) and had any post-baseline safety information.

Age, Continuous
Age, Continuous(years)Part 1Part 2Total
Mean62.9 ± 8.7964.5 ± 9.4163.9 ± 9.18
Sex: Female, Male
Sex: Female, Male(Participants)Part 1Part 2Total
Female425294
Male3771108
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1Part 2Total
Hispanic or Latino2911
Not Hispanic or Latino7597172
Unknown or Not Reported21719
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1Part 2Total
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander011
Black or African American142135
White6286148
More than one race2810
Unknown or Not Reported156
08

Study locations

61 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • Mayo Clinic (AZ)
    Scottsdale, Arizona 85259, United States
  • City of Hope
    Duarte, California 91010, United States
  • Jonnsson Comprehensive Cancer Center / University of Los Angeles
    Los Angeles, California 90095, United States
  • Smilow Cancer Hospital
    New Haven, Connecticut 06510, United States
  • University of Florida Health Cancer Center- Shands Cancer Center Hospital
    Gainesville, Florida 32608, United States
  • Sylvester, University of Miami
    Miami, Florida 33136, United States
  • H. Lee Moffitt Cancer Center Research Institute
    Tampa, Florida 33612, United States
  • Emory University / Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • Kaiser Permanente- Hawaii
    Honolulu, Hawaii 96819, United States
  • University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Johns Hopkins Medicine
    Baltimore, Maryland 21287, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Karmanos Cancer Institute / Wayne State University
    Detroit, Michigan 48201, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Washington University St. Louis
    Saint Louis, Missouri 63110, United States
  • Hackensack University Medical Center / John Therurer Cancer Center
    Hackensack, New Jersey 07601, United States
  • Valley Hospital
    Paramus, New Jersey 07652, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14203, United States
  • NYU Perlmutter Cancer Center
    New York, New York 10016, United States
  • Mt Sinai NYC
    New York, New York 10029, United States
  • Columbia University
    New York, New York 10032, United States
  • UNC-Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Kaiser Permanente Northwest OR
    Portland, Oregon, United States
  • Abramson Cancer Center of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Swedish Cancer Institute
    Seattle, Washington 98109, United States
  • University Hospital Krems, Department of Internal Medicine II
    Krems, Austria
  • Salzburg Regional Hospital Müllner
    Salzburg, Austria
  • Medical University Vienna, Department of Internal Medicine I
    Vienna, Austria
  • ZNA Stuivenberg
    Antwerp, Belgium
  • General Hospital Saint-Jan
    Brugge, Belgium
  • Jules Bordet Institute
    Brussels, 1000, Belgium
  • UCL Saint-Luc
    Brussels, B-1200, Belgium
  • University Hospital Ghent
    Ghent, Belgium
  • University Hospital Leuven, Campus Gasthuisberg
    Leuven, Belgium
  • UCL Mont-Godinne
    Yvoir, B-5530, Belgium
  • Claude Huriez Hospital, Department of Blood Diseases
    Lille, 59037, France
  • South Lyon Hospital Center, Department of Clinical Hematology
    Lyon, 69002, France
  • Brabois Adults Hospital
    Nancy, 54000, France
  • Nantes University Hospital Center
    Nantes, 44093, France
  • Hopital Saint-Antoine, Service d´Hematologie Clinique et Therapie Cellulaire
    Paris, 75012, France
  • La Pitie-Salpetriere University Hospital, Department of Clinical Hematology
    Paris, 75013, France
  • Necker Children's Hospital
    Paris, 75015, France
  • BAG Oncology Gemeinschaftspraxis
    Dresden, 01307, Germany
  • University Hospital Freiburg, Department of Internal Medicine I
    Freiburg, D-79106, Germany
  • Universitätsklinikum Heidelberg Medizinische Klinik V
    Heidelberg, 69120, Germany
  • Universitätsklinikum des Saarlandes Klinik für Innere Medizin I
    Homburg, 66421, Germany
  • Universitätsmedizin Mainz
    Mainz, 55122, Germany
  • University hospital of Tuebingen, Internal Medicine II
    Tübingen, Germany
  • Med. Klinik und Poliklinik II Universitätsklinikum
    Würzburg, Germany
  • National & Kapodistrain University of Athens School of Medicine, Alexandra Hospital
    Athens, 11528, Greece
09

References and documents

Publications

  • Tremblay G, Daniele P, Breeze J, Li L, Shah J, Shacham S, Kauffman M, Engelhardt M, Chari A, Nooka A, Vogl D, Gavriatopoulou M, Dimopoulos MA, Richardson P, Biran N, Siegel D, Vlummens P, Doyen C, Facon T, Mohty M, Meuleman N, Levy M, Costa L, Hoffman JE, Delforge M, Kaminetzky D, Weisel K, Raab M, Dingli D, Tuchman S, Laurent F, Vij R, Schiller G, Moreau P, Richter J, Schreder M, Podar K, Parker T, Cornell RF, Lionel K, Choquet S, Sundar J. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer. 2021 Sep 6;21(1):993. doi: 10.1186/s12885-021-08453-9. PubMed 34488662 ↗
  • Nikolaou A, Ambavane A, Shah A, Ma W, Tosh J, Kapetanakis V, Willson J, Wang F, Hogea C, Gorsh B, Gutierrez B, Sapra S, Suvannasankha A, Samyshkin Y. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis. Expert Rev Hematol. 2021 Dec;14(12):1137-1145. doi: 10.1080/17474086.2021.1970522. Epub 2021 Sep 20. PubMed 34465265 ↗
  • Chari A, Florendo E, Mancia IS, Cho H, Madduri D, Parekh S, Richter J, Dhadwal A, Thomas J, Jiang G, Lagana A, Bhalla S, Jagannath S. Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Dec;21(12):e975-e984. doi: 10.1016/j.clml.2021.07.014. Epub 2021 Jul 18. PubMed 34404623 ↗
  • Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455. PubMed 31433920 ↗
  • Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 Mar 20;36(9):859-866. doi: 10.1200/JCO.2017.75.5207. Epub 2018 Jan 30. PubMed 29381435 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Jul 2019, 50 months.

Results were first posted in Aug 2020, 1 year after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 50 months is above that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2015
First posted
Jan 13, 2015
StartActual
May 26, 2015
Primary completionActual
Jul 26, 2019
CompletionActual
Jul 26, 2019
Results first posted
Aug 13, 2020
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02336815
Responsible party
Sponsor
First posted
Jan 13, 2015
Start date
May 26, 2015
Primary completion
Jul 26, 2019
Completion
Jul 26, 2019
Results posted
Aug 13, 2020
Last update
Jan 26, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion